Navigating the Sotatercept landscape: A meta-analysis of clinical outcomes

Pulmonary arterial hypertension (PAH) is a widespread condition that affects around 1% of the global population, with a higher prevalence among older individuals. The approach to managing PAH has undergone significant changes, requiring extensive treatment strategies. Sotatercept, an FDA-approved medication, has recently attracted attention for its potential role in PAH therapy. However, information on its safety and effectiveness is scarce. In this study, we performed a meta-analysis of existing randomized clinical trials to assess the impact of Sotatercept on PAH patients. Our findings revealed that those treated with Sotatercept showed greater improvement in pulmonary vascular resistance and World Health Organization functional class compared with placebo recipients. The occurrence of adverse events was similar between both groups. Importantly, the Sotatercept group displayed a considerably higher number of cases with an increase in hemoglobin levels. Considering that about 33% of PAH patients experience anemia and both anemia and polycythemia can adversely affect disease prognosis, additional research is necessary to establish the potential advantages and disadvantages of Sotatercept as a treatment choice, specifically regarding its erythropoietic properties. In this study, we performed a meta-analysis on two randomized clinical trials to assess the impact of Sotatercept on PAH patients. The included papulation were 429 patients with PAH, of which 237 received Sotatercept and 192 received placebo. They were followed for 6 months.Our findings revealed that those treated with Sotatercept showed greater improvement in pulmonary vascular resistance, right atrial pressure, mean pulmonary artery pressure, change in N-terminal pro-B-type natriuretic peptide, and World Health Organization functional class compared with placebo recipients.image